The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain

Steroids

Volumn 74, Issue 1, 2009, Pages 13-19

  Cibickova, Lubica ^a   Radomir, Hyspler ^b   Stanislav, Micuda ^a   Cibíček, Norbert ^a   Helena, Zivna ^a   Daniel, Jun ^c   Alena, Ticha ^b   Eva, Brcakova ^a   Vladimir, Palicka ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acetylcholinesterase; Amyloid beta; Cholesterol synthesis; Rat brain; Statins

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LATHOSTEROL; SIMVASTATIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; LIPID BRAIN LEVEL; MALE; NONHUMAN; RAT;

RATTUS;

EID: 57349169311     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2008.08.007     Document Type: Article

References (37)

1. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59 2 (2002) 223-227
2. Zamrini E., McGwin G., and Roseman J.M. Association between statin use and Alzheimer's disease. Neuroepidemiology 23 1-2 (2004) 94-98
3. Sparks D.L. Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol Aging 17 (1996) 291-299
4. Bergmann C.H. Diversification of gamma-secretase activity versus beta-secretase inhibition by cholesterol depletion. Neurobiol Aging 21 (2000) 278
5. Hu W., Gray N.W., and Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J Neurochem 86 (2003) 470-478
6. Bligh E.G., and Dyer W.J. A rapid mathod of total lipid extraction and purification. Can J Biochem Physiol 37 (1959) 911-917
7. Diraison F., Pachiaudi C., and Beyot M. In vivo measurement of plasma cholesterol and fatty acid synthesis with deuterated water: determination of the average number of deuterium atoms incoporated. Metabolism 45 7 (1996) 817-821
8. 3] acetone and gas chromatography-mass spectometry. Anal Biochem 258 (1998) 315-321
9. Ellman G.L., Courtney K.D., Andres V.L., and Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7 (1961) 88-95
10. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ 1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996) 1005-1013
11. Lutjohann D., Stroick M., Bertsch T., Kuhl S., Lindenthal B., Thelen K., et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69 6 (2004) 431-438
12. Johnson-Anuna L.N., Eckert G.P., Keller J.H., Igbavboa U., Franke C., Fechner T., et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharm Exp Ther 312 (2005) 786-793
13. Petanceska S.S., DeRosa S., Olm V., Diaz N., Sharma A., Thomas-Bryant T., et al. Statin therapy for Alzheimer's disease. Will it work?. J Mol Sci 16 (2002) 155-161
14. Thelen K.M., Rentsch K.M., Gutteck U., Heverin M., Olin M., Andersson U., et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not pravastatin. J Pharmacol Exp Ther 316 3 (2006) 1146-1152
15. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 (1999) 413-428
16. Franke C., Noldner M., Abdel-Kader R., Johnson-Anuna L.N., Wood W.G., Muller W.E., et al. Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis 25 (2007) 438-445
17. Saheki A., Terasaki T., Tamai I., and Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 11 2 (1994 Feb) 305-311
18. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 (1999) 498-511
19. Sparks D.L., Connor D.J., Browne P.J., Lopez J.E., and Sabbagh M.N. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging 6 5 (2002) 324-331
20. Tanaka N., Katayama Y., Katsumata T., Otori T., and Nishiyama Y. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flox in stroke-prone spontaneously hypertensive rats. Brain Res 169 (2007) 125-132
21. Tsui A., Saheki A., Tamai I., and Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the blood-brain barrier. J Pharmacol Exp Ther 267 3 (1993) 1085-1090
22. Malhotra H.S., and Goa K.L. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61 12 (2001) 1835-1881
23. de Lange E.C.M., de Boer A.G., and Breimer D.D. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45 (2000) 125-148
24. Kuo Y.M., Emmerling M.R., Bisgaier C.L., Essenburg A.D., Lampert H.C., Drumm D., et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain A-beta 1-42 levels. BBRC 252 (1998) 711-715
25. Arvanitakis Z., Lucas J.A., and Graff-Radford N.R. Correlation between serum cholesterol parameters and plasma amyloid beta protein. Neurobiol Aging 21 (2000) 96
26. Buxbaum J.D., Geoghagen N.S., and Friedhoff L.T. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis 3 2 (2001) 221-229
27. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59 (2002) 1257-1258
28. Hoglund K., Wiklund O., Vanderstichele H., Eikenberg O., Vanmechelen E., and Blenow K. Plasma levels of beta-amyloid (1-40), beta-amyloid (1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61 3 (2004) 333-337
29. Hoglund K., Syversen S., Lewczuk P., Wallin A., Wiltfang J., and Blennow K. Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer's disease. Exp Brain Res 164 (2005) 205-214
30. Sjogren M., Gustafsson K., Syversen S., Olsson A., Edman A., Davidsson P., et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 16 1 (2003) 25-30
31. Cibickova L., Palicka V., Cibicek N., Cermakova E., Micuda S., Bartosova L., et al. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiol Res 56 6 (2007) 765-770
32. Dietschy J.M., and Turley S.D. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45 (2004) 1375-1397
33. Wells M.A., and Dittmer J.C. A comprehensive study of the postnatal changes in the concentration of the lipids of developing rat brain. Biochemistry 6 10 (1967) 3169-3175
34. Serougne C., Lefevre C., and Chevallier F. Cholesterol transfer between brain and plasma in the rat: a model for the turnover of cerebral cholesterol. Exp Neurol 51 (1976) 229-240
35. Jurevics H., Hostettler J., Barrett C., Morell P., and Toews A.D. Diurnal and dietary-induced changes in cholesterol synthesis correlate with levels of mRNA ofr HMG-CoA reductase. J Lipid Res 41 (2000) 1048-1053
36. Guan G., Xie Ch., Dietschy J.M., and Turley S.D. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Dev Brain Res 146 (2003) 87-98
37. Refolo L.M., Pappolla M.A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7 (2000) 321-331